On March 12, 2019, InventisBio announced the completion of a $70 million (about 500 million yuan) round of financing.This round of financing is invested by shang shang.Zhaoyin international co-leader, pudong kechuang.Lilly Asia Fund and Aobo Asia Capital are mainly used for the promotion of clinical pipeline products of Yifang Biology and the development of several preclinical "first-in-class" innovative drugs.
Yifang Biology is located in Zhangjiang Pharmaceutical Valley in Shanghai and focuses on cancer.The development of innovative drugs for major diseases such as metabolism is also actively developing other innovative drugs for cancer immune combination therapy.Yifang Biological has rich registration in clinical development in the United States and China.Regulatory and operational experience, showing high efficiency in the conduct of clinical trials, with the first clinical phase I completed in less than a year.At the beginning of its establishment, Yifang Biology obtained the angel investment of Beautiful State Capital. In 2016, it obtained the round A financing led by Lilly Asia Fund, and in 2017, it obtained the round B financing led by Aobo Asia and invested by Lilly Asia Fund, with a total financing of more than 200 million yuan.
One of the core products of Yifang Biological Co., Ltd., EGFR T790M inhibitor D-0316 for lung cancer, showed better safety and similar efficacy than similar marketed products in phase I clinical trial.It was due to its outstanding competitiveness that Betta and Yifang Biological reached an agreement in December 2018 to obtain D-0316 for a first payment of 230 million yuan and subsequent R & D mileage in China (including Hong Kong.Taiwan) for exclusive development rights.If D-0316 is successfully marketed, Betta Pharmaceuticals will also be required to pay sales mileage and sales share to Yifang Biology in accordance with the agreed treaty.
D-0316 Phase II clinical study information for non-small cell lung cancer was just announced on the national clinical trial registration platform on February 27, including patients with locally advanced or metastatic non-small cell lung cancer with T790M mutation after previous treatment with first- or second-generation EGFR-TKIs. It is planned to enroll 300 patients.At present, there is no domestic T790M inhibitor approved for marketing. The global sales of originator Osimertinib in 2018 reached 1.86 billion US dollars, of which the sales revenue in China exceeded 2 billion yuan.Betta Pharmaceutical Co., Ltd. is a leader in the marketing and sales of lung cancer products, which will be a great advantage for the commercialization of D-0316 in the future.
In addition to D-0316, Yifang Biological's products under development include selective estrogen receptor degrader (SERD) D-0502 for the treatment of breast cancer and uric acid transporter 1 (URAT1) inhibitor D-0120 for the treatment of gout.
D-0502 has been substantially optimized compared to other selective estrogen receptor degraders in terms of pharmacokinetics, improving not only efficacy but also safety.The preclinical data of D-0502 was published by Yifang Biological at the American Association for Cancer Research Annual Meeting (AACR) in March 2018, and the phase I study plan and preliminary results of D-0502 alone and in combination with CDK4/6 inhibitor Palbociclib for advanced or metastatic ER +/HER2- breast cancer were presented in a poster at the San Antonio Breast Cancer Conference (SABC) in late 2018.
In the preclinical product pipeline, Yifang Biology is also laying out a number of cancer immunity, tumor-targeted drugs, and metabolic disease-related First-in-Class or Best-in-Class drug development.
Yifang Biology Chairman Wang Yaolin
Dr. Wang Yaolin, Chairman and CEO of Yifang Biology, said: "This financing will help us to further develop innovative drugs with independent intellectual property rights and carry out international multicenter clinical trials so that patients in various countries can benefit from new drugs developed by Yifang Biology.At the same time, it will also help our team to expand and hope that more outstanding R & D talents will join the entrepreneurial team of Yifang Biology.We are pleased to receive support from well-known funds and investors such as Shang Kang Investment and Zhaobin International.The further capital injection of Lilly Asia Fund, the lead investor in the first two rounds of financing, and Aobo Asia Capital in this round of financing also shows the confidence of our strategic investors in the future global pharmaceutical market of the Yifang Biology Team and the company's clinical products.
"As an innovative drug R & D enterprise, Yifang Biology has clear design ideas, focuses on the balance between innovation and druggability, gives full play to the technical accumulation of the founding team in terms of small molecule chemical structure, and combines clinical experience to make innovations with significant clinical value for mechanistically confirmed drug targets," said Ju Yumin, partner of Shangshang Investment and co-head of medical investment.After years of accumulation, built a unique technology platform and high-quality R & D pipeline.Medicine and health is one of the key investment areas of Shangshang.The large extensibility of the platform accords with the investment idea of Shangshang.It is a great honor for Shangshang Investment to help Yifang Biology and promote the R & D and clinical trials of innovative varieties for the benefit of patients.
About Sangkang Investment
Shangshang Investment is a private equity fund focused on the Chinese market, focusing on innovation-driven growth investment opportunities, mainly in technology and innovation.Medical and pharmaceutical health services.
About VB International
(p) Zhaobin International Finance Co., Ltd. ("Zhaobin International") is a Hong Kong-based company.Deep in the mainland.The whole world.Specialized integrated financial services organization.As a wholly owned subsidiary of China Merchants Bank Co., Ltd., ZhaoBin International and its subsidiaries rely on the advantages of coordination and linkage at home and abroad, relying on the strong strength and outstanding social reputation of the parent bank, actively implementing diversified business strategies, and comprehensively distributing enterprise financing.Asset Management.Wealth management.Stocks.Structured finance and other business sections.
About Pudong Kechuang
Pudong Kechuang Group is mainly engaged in venture capital investment.Fund management.Technology guarantee.Technology loans.Science and technology incubation and other science and technology financial business, focusing on independent innovation of high-tech enterprises, including integrated circuits.Biomedicine.High-end equipment.Internet/new media and other industries supported by national policies.
Yifang Biology Official Website:http://doc.pharmcube.com/imagebc08210757874eb498e39e27ca8fc185